Sorrento Therapeutic’s vision for immunotherapies is guided by two core principles:
First, the pursuit of targets regardless of their location, whether extracellular, intracellular, or membrane-bound antigens. As an example of our progress towards this goal, Sorrento Therapeutics and City of Hope announced the formation of a joint venture company, LA Cell, in September of 2015 and the exclusive licensing by LA Cell of technology pioneered at City of Hope to develop first-in-class immunotherapies against intracellular targets (“cell internalizing antibodies”).
The second principle driving Sorrento is the application of technologies to enable an “off-the-shelf” strategy by leveraging existing antibodies or cell products that Sorrento can modify to generate new treatment modalities. Towards this goal in 2013, Sorrento acquired ADC technology with proprietary toxin payload and conjugation chemistries that rely on chemical modifications to convert existing antibodies into new ADC therapies. An analogous biochemical approach is the foundation for Sorrento’s bispecific antibody technology.
Currently our lead immuno-oncology G-MAB programs STI-A1110 and STI-A1014 are targeting the important immune checkpoints PD-1 and PD-L1. Both programs are currently in IND-enabling studies. Sorrento is also working on additional immuno-oncology programs and targets.
Sorrento has partnered its PD-L1 program STI-A1014 with Lee’s Pharma, a public biopharmaceutical company listed on the main board of Hong Kong Stock Exchange (0950) with over 20 years of operation in China’s pharmaceutical industry. Lee’s Pharma will develop the antibody for the greater Chinese market, including Mainland China, Hong Kong, Macau, and Taiwan.